Grand Rounds: Office assessment of urinary incontinence

A new randomized trial shows Er:YAG laser therapy offers no significant benefit over sham treatment for managing female stress urinary incontinence at 6 months.

GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.

In this Q&A, Karyn S. Eilber, MD, shares some of the biggest takeaways from the new AUA/SUFU/AUGS 2025 Guidelines on Genitourinary Syndrome of Menopause.

A new study finds no significant difference in symptom improvement between onabotulinumtoxinA injections and midurethral sling surgery for women with mixed urinary incontinence.

A new study reveals that virtual pelvic floor therapy is just as effective as in-person treatment for postpartum women with stress urinary incontinence.

New guidelines on GSM recommends symptom-based diagnosis, shared decision-making, and local estrogen as first-line therapy to improve quality of life.